TrialESMO open2023

Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study).

C Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.